Brokerages Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) Price Target at $18.86

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been given an average recommendation of “Reduce” by the eight analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $18.8571.

A number of equities research analysts have weighed in on IART shares. BMO Capital Markets began coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price target for the company. Truist Financial lifted their price objective on Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Thursday, June 18th. Wall Street Zen lowered shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Citigroup restated a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $16.89 on Monday. The company has a market capitalization of $1.31 billion, a P/E ratio of -187.65, a P/E/G ratio of 1.42 and a beta of 1.21. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. The company has a 50 day simple moving average of $17.93 and a 200-day simple moving average of $14.27. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $20.49.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. The firm had revenue of $418.76 million for the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities research analysts predict that Integra LifeSciences will post 2.46 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently modified their holdings of the company. Osaic Holdings Inc. lifted its position in Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the period. State of Tennessee Department of Treasury increased its position in Integra LifeSciences by 7.9% during the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock worth $332,000 after purchasing an additional 1,964 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after buying an additional 1,975 shares in the last quarter. Capital Fund Management S.A. lifted its holdings in shares of Integra LifeSciences by 5.7% in the 3rd quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock valued at $535,000 after buying an additional 1,997 shares during the period. Finally, Global Retirement Partners LLC purchased a new stake in shares of Integra LifeSciences in the fourth quarter valued at approximately $25,000. 84.78% of the stock is owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.